Skip to main content
Top
Published in: Acta Diabetologica 1/2015

01-02-2015 | Original Article

Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study

Authors: Claudia R. L. Cardoso, Nathalie C. Leite, Marcel T. Ferreira, Gil F. Salles

Published in: Acta Diabetologica | Issue 1/2015

Login to get access

Abstract

The prognostic importance of baseline and serial glycated hemoglobin (HbA1c) changes for cardiovascular outcomes is still debated. We aimed to evaluate it in 620 high-risk individuals with type 2 diabetes (mean age 60.4 years, 37 % males, 55 % Caucasians). Patients had HbA1c levels measured at study entry and serially during follow-up. Primary end points were total cardiovascular events (CVEs), major CVEs (non-fatal myocardial infarctions and strokes plus cardiovascular deaths) and all-cause mortality. Cardiovascular and non-cardiovascular mortalities were secondary end points. HbA1c was evaluated either as a continuous variable and categorized at clinically relevant cutoffs. Multivariate Cox regressions assessed the associations with end points. After a median follow-up of 6.6 years, 125 total CVEs occurred (90 major CVEs), and 111 patients died (64 from cardiovascular diseases). After statistical adjustments for other cardiovascular risk factors, baseline and mean first-year HbA1c predicted all end points, except non-cardiovascular deaths; and hazard ratios tended to be higher for mean first year than for baseline HbA1c. Each 1 % (10.9 mmol/mol) increase in mean first-year HbA1c increased 27 % the risk of major CVEs occurrence (95 % CI 11–45 %). Updating HbA1c for values obtained beyond the second year of follow-up did not improve its predictive performance. The cardiovascular protection was observed until HbA1c values lower than 6.5 % (48 mmol/mol). Moreover, the magnitude of HbA1c reduction during the first year of follow-up was predictive of better cardiovascular outcomes, independent of baseline HbA1c levels. In conclusion, better glycemic control, especially during the first year of follow-up, is determinant of better cardiovascular outcomes in high-risk patients with type 2 diabetes, without any detectable lower threshold level of HbA1c.
Literature
1.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053PubMedCrossRef Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053PubMedCrossRef
2.
go back to reference Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841PubMedCrossRef Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841PubMedCrossRef
3.
go back to reference Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165:1910–1916PubMedCrossRef Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165:1910–1916PubMedCrossRef
4.
go back to reference Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W et al (2012) Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 55:2348–2355PubMedCrossRef Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W et al (2012) Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 55:2348–2355PubMedCrossRef
5.
go back to reference Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G (2014) HbA1c and coronary heart disease risk among diabetic patients. Diabetes Care 37:428–435PubMedCentralPubMedCrossRef Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G (2014) HbA1c and coronary heart disease risk among diabetic patients. Diabetes Care 37:428–435PubMedCentralPubMedCrossRef
6.
go back to reference Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431PubMedCrossRef Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431PubMedCrossRef
7.
go back to reference Zhang Y, Hu G, Yuan Z, Chen L (2012) Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 7:e42551PubMedCentralPubMedCrossRef Zhang Y, Hu G, Yuan Z, Chen L (2012) Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 7:e42551PubMedCentralPubMedCrossRef
8.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
9.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
10.
go back to reference Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef
11.
go back to reference ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef
12.
go back to reference Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, VADT Investigators et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, VADT Investigators et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef
13.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef
14.
go back to reference Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772PubMedCrossRef Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772PubMedCrossRef
15.
go back to reference Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394–403PubMedCrossRef Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394–403PubMedCrossRef
16.
go back to reference Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J (2013) Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 11:CD008143PubMed Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J (2013) Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 11:CD008143PubMed
17.
go back to reference Yudkin JS, Richter B, Gale EA (2010) Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:2079–2085PubMedCrossRef Yudkin JS, Richter B, Gale EA (2010) Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:2079–2085PubMedCrossRef
18.
go back to reference Ferguson LD, Sattar N (2013) Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted? Diabetes Obes Metab 15:387–391PubMedCrossRef Ferguson LD, Sattar N (2013) Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted? Diabetes Obes Metab 15:387–391PubMedCrossRef
19.
go back to reference Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR (2013) Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 31:2176–2186PubMedCrossRef Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR (2013) Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 31:2176–2186PubMedCrossRef
20.
go back to reference Cardoso CR, Leite NC, Ferreira MT, Salles GF (2013) Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetes Care 36:3772–3778PubMedCentralPubMedCrossRef Cardoso CR, Leite NC, Ferreira MT, Salles GF (2013) Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetes Care 36:3772–3778PubMedCentralPubMedCrossRef
21.
go back to reference Cardoso CR, Marques CE, Leite NC, Salles GF (2012) Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients. J Hypertens 30:940–947PubMedCrossRef Cardoso CR, Marques CE, Leite NC, Salles GF (2012) Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients. J Hypertens 30:940–947PubMedCrossRef
22.
go back to reference American Diabetes Association (2005) Standards of medical care in diabetes. Diabetes Care 28(suppl 1):S4–S36 American Diabetes Association (2005) Standards of medical care in diabetes. Diabetes Care 28(suppl 1):S4–S36
23.
go back to reference Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCentralPubMedCrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCentralPubMedCrossRef
24.
go back to reference Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL et al (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489PubMedCrossRef Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL et al (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489PubMedCrossRef
25.
go back to reference Landman GW, van Hateren KJ, Kleefstra N, Groenier KH, Gans RO, Bilo HJ (2010) The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). Br J Gen Pract 60:172–175PubMedCentralPubMedCrossRef Landman GW, van Hateren KJ, Kleefstra N, Groenier KH, Gans RO, Bilo HJ (2010) The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). Br J Gen Pract 60:172–175PubMedCentralPubMedCrossRef
26.
go back to reference Khunti K, Weston C, Gholap N, Molokhia M, Paul S, Millett C et al (2013) All-cause mortality in relation to glycated haemoglobin in individuals with newly diagnosed type 2 diabetes: a retrospective cohort study. Br J Diab Vasc Dis 13:22–30CrossRef Khunti K, Weston C, Gholap N, Molokhia M, Paul S, Millett C et al (2013) All-cause mortality in relation to glycated haemoglobin in individuals with newly diagnosed type 2 diabetes: a retrospective cohort study. Br J Diab Vasc Dis 13:22–30CrossRef
27.
go back to reference Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A, Kaplan SH (2009) Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 151:854–860PubMedCrossRef Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A, Kaplan SH (2009) Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 151:854–860PubMedCrossRef
28.
go back to reference Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Action to Control Cardiovascular Risk in Diabetes Investigators et al (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33:983–990PubMedCentralPubMedCrossRef Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Action to Control Cardiovascular Risk in Diabetes Investigators et al (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33:983–990PubMedCentralPubMedCrossRef
29.
go back to reference Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119:351–357PubMedCrossRef Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119:351–357PubMedCrossRef
30.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef
31.
go back to reference American Diabetes Association (2014) Standards of medical care in diabetes. Diabetes Care 37(suppl 1):S14–80 American Diabetes Association (2014) Standards of medical care in diabetes. Diabetes Care 37(suppl 1):S14–80
Metadata
Title
Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study
Authors
Claudia R. L. Cardoso
Nathalie C. Leite
Marcel T. Ferreira
Gil F. Salles
Publication date
01-02-2015
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2015
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0592-0

Other articles of this Issue 1/2015

Acta Diabetologica 1/2015 Go to the issue

Thanks to Reviewers

Thanks to Reviewers 2014